‘For many people with drug problems, employment may help support and sustain recovery from addiction. Drugscope supports the government’s commitment to help drug addicts in the world of work, as part of an extensive program of recovery. However, while people in drug treatment and recovery want to access training and employment, they can face enormous obstacles, including the stigma associated with drug or alcohol dependency.Research and experience shows that most employers do not consciously take someone with a history of drug problems, even if they are otherwise unable to do the job London Drug and Alcohol Network , part of Drugscope, was funded by the Trust in London in four years to improve the way in which the employment of people with drug and alcohol problems. This means working to overcome barriers such as stigma and employers to increase the number of opportunities for education, training and employment available to this group of patients. The project also aims to develop a knowledge base of what works in the world of work claimed for people with drug and alcohol problems and to influence policy and strategy in this area.
The DWP figures show that the total number of asylum seekers, IB , 1.8 % are drug addicts and two % a dependency on alcohol. However, an addiction to drugs or alcohol is not enough to make someone the right to receive IB.
‘Most people with an addiction to drugs or alcohol also have physical problems that can affect their ability to work. While an addiction to drugs or alcohol can be very debilitating, is not itself a right or’ passport ‘for the benefit, which may be suggested by the figures published today. People with drug or alcohol must meet all eligibility requirements for benefits, including evidence of such disability, and may be required to undergo a medical examination to determine eligibility .
The study will provide data to confirm that the characteristics of RPC1063 meet pre-specified pharmacokinetic , pharmacodynamics and safety criteria. The safety features also includes the observation of cardiovascular events, liver, lungs and eyes.
The objective of Phase 1 will be the use of pharmacokinetic, pharmacodynamic relationship RPC1063 to select the exact dose levels for phase 2 evaluation.